Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240006/S019

VARIPULSE Platform (VARIPULSE Catheter; TRUPULSE Generator; Sterile Interface Cable; nGEN Pump)

Biosense Webster, Inc. · Decision date Sep 10, 2026

MEDTECHLEDGER EXPLANATIONP240006/S019

What did the FDA decide?

The FDA database entry records a 30-day notice for supplement S019 to PMA P240006, submitted by Biosense Webster, Inc. The stated purpose is to implement a repackaging and relabeling operation for the VARIPULSE Platform, which includes the VARIPULSE Catheter, TRUPULSE Generator, Sterile Interface Cable, and nGEN Pump. The supplement type is a process change involving the manufacturer, sterilizer, packager, or supplier.

The decision field shows OK30, and the supplement reason is listed as a process change. The device category describes a percutaneous cardiac ablation catheter for treating atrial fibrillation with irreversible electroporation. The notice does not state that the device received a new approval or that safety or effectiveness was independently demonstrated. Specific details about the new packaging or labeling content are not provided in the source fields.

FDA approval order statement

to implement a repackaging and relabeling operation
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Sep 10, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P240006/S019
Regulatory pathway
PMA supplement
Product code
QZI
Decision code
OK30
Decision date
Sep 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Product code
QZI
FDA device class
3

For the original device and its historical approval scope, see PMA P240006. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240006 · Original PMA

    VARIPULSE Platform (VARIPULSE Catheter; TRUPULSE Generator; Sterile Interface Cable; nGEN Pump)

  2. P240006/S019 received

    Application receipt date recorded by FDA.

  3. P240006/S019 · FDA decision

    30-Day Notice

  4. P240006/S020 · Related supplement

    VARIPULSE BI-DIRECTIONAL CATHETER

  5. P240006/S018 · Related supplement

    Varipulse Bi-Directional Catheter

Timeline entries are records held by MedtechLedger for P240006. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240006

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA approvalNov 6, 2024FDA
Biosense Webster, Inc.PMA supplementSep 15, 2026FDA
Biosense Webster, Inc.PMA supplementNov 3, 2026FDA

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Kardium, Inc.PMA supplementOct 27, 2026FDA
Kardium, Inc.PMA supplementOct 23, 2026FDA
Volt PFA SystemP250022/S002
ABBOTT MEDICALPMA supplementOct 15, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biosense Webster, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
31 Technology Dr., Suite 200, Irvine, CA, 91618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records